Episode Player
NOXOPHARM LTD (NOX) - A New Immune System Discovery Could Change Drug Development
ASX BRIEFS
A single scientific insight can open up an entire pipeline, and that’s what makes this conversation with Noxopharm Limited so compelling. We’re joined by CEO Olivier Laczka to talk about Sofra™, the company’s RNA technology platform built on a breakthrough discovery about how the immune system triggers inflammation, developed alongside the Hudson Institute of Medical Research in Melbourne and published in a leading journal. If you care about where ASX biotech is heading, this is a clear look at how platform science turns into real drug programs.
We dig into SOF-SKN™, Noxopharm’s lead asset aimed at cutaneous lupus, a skin disease with a growing global market and no specific designed treatments. Olivier explains why a topical cream that blocks lupus-linked inflammation could be a meaningful shift for patients, and he shares the latest progress including a completed safety trial in healthy volunteers and the practical next step of moving into a trial with lupus patients. We also touch on how the same approach could expand into broader inflammatory skin diseases and chronic conditions where inflammation drives long-term damage.
Then we move into immuno-oncology, where Sofra™ isn’t used to dampen inflammation but to deliberately boost targeted immune activation for cancer treatment. Olivier walks us through newly released breakthrough data, including a 200-fold increase in immune activation when combined with a clinical stage TLR8 agonist in human skin biopsies ex vivo, plus supportive animal model results, and why IP protection and US patents matter when scaling a platform globally. Finally, we cover validation through an Australian Government MRFF grant linked to pelvic floor disorders and birth injury repair, and the key 6 to 12 month milestones investors watch: manufacturing, FDA engagement for IND preparation, cancer program progress, and growing international partnerships.
If you enjoyed this deep dive into RNA therapeutics, inflammation research, and clinical stage biotech execution, subscribe, share the episode with a mate, and leave a review to help more listeners find the show.
